Aerovate Therapeutics (AVTE) Stock Forecast, Price Target & Predictions
AVTE Stock Forecast
Aerovate Therapeutics stock forecast is as follows: an average price target of $13.00 (represents a 413.83% upside from AVTE’s last price of $2.53) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
AVTE Price Target
The average price target for Aerovate Therapeutics (AVTE) is $13.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $2.00. This represents a potential 413.83% upside from AVTE's last price of $2.53.
AVTE Analyst Ratings
According to 5 Wall Street analysts, Aerovate Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for AVTE stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 5 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Aerovate Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 17, 2024 | Liisa Bayko | Evercore ISI | $2.00 | $1.65 | 21.21% | -20.95% |
| Jun 17, 2024 | Eun Yang | Jefferies | $2.00 | $1.65 | 21.21% | -20.95% |
| Apr 01, 2024 | Tiago Fauth | Wells Fargo | $35.00 | $29.57 | 18.36% | 1283.40% |
| Mar 25, 2024 | Eun Yang | Jefferies | $65.00 | $26.95 | 141.19% | 2469.17% |
The latest Aerovate Therapeutics stock forecast, released on Jun 17, 2024 by Liisa Bayko from Evercore ISI, set a price target of $2.00, which represents a 21.21% increase from the stock price at the time of the forecast ($1.65), and a -20.95% decrease from AVTE last price ($2.53).
Aerovate Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $26.00 |
| Last Closing Price | $2.53 | $2.53 | $2.53 |
| Upside/Downside | -100.00% | -100.00% | 927.67% |
In the current month, the average price target of Aerovate Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aerovate Therapeutics's last price of $2.53. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 18, 2024 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| Jun 17, 2024 | Cowen & Co. | Hold | Downgrade | |
| Jun 17, 2024 | Guggenheim | Neutral | Downgrade | |
| Jun 17, 2024 | Jefferies | Hold | Downgrade | |
| Jun 17, 2024 | BTIG | Buy | Neutral | Downgrade |
| Apr 01, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Dec 06, 2022 | BTIG | Buy | Upgrade |
Aerovate Therapeutics's last stock rating was published by Wells Fargo on Jun 18, 2024. The company Downgrade its AVTE rating from "Overweight" to "Equal-Weight".
Aerovate Therapeutics Financial Forecast
Aerovate Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $6.82M | $6.79M | $6.75M | - | - | - | - | - | - | - | - |
| High Forecast | $6.82M | $6.79M | $6.75M | - | - | - | - | - | - | - | - |
| Low Forecast | $6.82M | $6.79M | $6.75M | - | - | - | - | - | - | - | - |
| # Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Aerovate Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AVTE's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Aerovate Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict AVTE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aerovate Therapeutics's previous annual EBITDA (undefined) of $NaN.
Aerovate Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-17.74M | $-16.54M | $-15.76M | $-21.08M | $-3.46M | $-5.20M | $-7.07M | $-8.51M | $-11.16M | $-13.49M | $-23.65M |
| High Forecast | $-17.74M | $-16.54M | $-15.76M | $-21.08M | $-3.46M | $-5.20M | $-7.07M | $-5.11M | $-5.30M | $-13.49M | $-23.65M |
| Low Forecast | $-17.74M | $-16.54M | $-15.76M | $-21.08M | $-3.46M | $-5.20M | $-7.07M | $-11.64M | $-16.74M | $-13.49M | $-23.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Aerovate Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AVTE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Aerovate Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Aerovate Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AVTE last annual SG&A of $NaN (undefined).
Aerovate Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.61 | $-0.57 | $-0.55 | $-0.73 | $-0.12 | $-0.18 | $-0.24 | $-0.29 | $-0.39 | $-0.47 | $-0.82 |
| High Forecast | $-0.61 | $-0.57 | $-0.55 | $-0.73 | $-0.12 | $-0.18 | $-0.24 | $-0.18 | $-0.18 | $-0.47 | $-0.82 |
| Low Forecast | $-0.61 | $-0.57 | $-0.55 | $-0.73 | $-0.12 | $-0.18 | $-0.24 | $-0.40 | $-0.58 | $-0.47 | $-0.82 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Aerovate Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AVTE previous annual EPS of $NaN (undefined).
Aerovate Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AVTE | Aerovate Therapeutics | $2.56 | $13.00 | 407.81% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| OPT | Opthea | $3.27 | $14.00 | 328.13% | Buy |
| ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
| ACRV | Acrivon Therapeutics | $7.21 | $22.50 | 212.07% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| ADAG | Adagene | $2.10 | $5.00 | 138.10% | Buy |
| RZLT | Rezolute | $4.44 | $6.67 | 50.23% | Buy |